L
Laurence Collette
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 281
Citations - 37642
Laurence Collette is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 78, co-authored 276 publications receiving 33811 citations. Previous affiliations of Laurence Collette include VU University Amsterdam & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)
Urs E. Studer,Laurence Collette,Peter Whelan,Walter Albrecht,Jacques Casselman,Theo M. de Reijke,Hartmut Knönagel,Wolfgang Loidl,Santiago Isorna,Subramanian K. Sundaram,Muriel Debois +10 more
TL;DR: Patients with a baseline PSA>50 ng/ml and/or a PSADT<12 mo were at increased risk to die from PCa and might have benefited from immediate ADT, whereas patients with a lower PSA were likely to die of causes unrelated to PCa, and thus could be spared the burden of immediateADT.
Journal ArticleDOI
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial
Philip Poortmans,Laurence Collette,Jean-Claude Horiot,Walter Van den Bogaert,Alain Fourquet,Abraham Kuten,Evert M. Noordijk,W.J. Hoogenraad,René-Olivier Mirimanoff,Marianne Pierart,Erik Van Limbergen,Harry Bartelink +11 more
TL;DR: There was no statistically significant difference in local control or survival between the high boost dose of 26 Gy and the low boost doses of 10 Gy in patients with microscopically incomplete excision of early breast cancer.
Journal ArticleDOI
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC “boost versus no boost” trial
Conny Vrieling,Laurence Collette,Ellen Bartelink,Jacques Borger,Stefan J. Brenninkmeyer,Jean-Claude Horiot,Marianne Pierart,Philip Poortmans,Henk Struikmans,Emmanuel van der Schueren,Joop A. van Dongen,Erik Van Limbergen,Harry Bartelink +12 more
TL;DR: There are some treatment sequelae, such as disturbing scars and skin changes, that can not be evaluated by BRA measurements, and the methods of cosmetic evaluation used in a study must be chosen in a way that balances reliability and comprehensiveness.
Journal ArticleDOI
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
R. de Wit,Gerrit Stoter,Dt Sleijfer,J.P. Neijt,W.W. ten Bokkel Huinink,L. de Prijck,Laurence Collette,Richard Sylvester +7 more
TL;DR: The sample size in this study is small as the study was prematurely discontinued when data became available from a competing study that showed no improved effectiveness of VIP compared with BEP, and it does not indicate that ifosfamide is superior to bleomycin in combination with cisplatin and etoposide.
Journal ArticleDOI
EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.
Oscar Matzinger,Erich Gerber,Zvi Bernstein,Philippe Maingon,Karin Haustermans,Jean François Bosset,Akos Gulyban,Philip Poortmans,Laurence Collette,Abraham Kuten +9 more
TL;DR: The GIWP-ROG defined guidelines for preoperative irradiation of adenocarcinomas of the GEJ and the stomach to reduce variability in the framework of future clinical trials.